ABSTRACT. Hypoxia influences tumor growth by inducing angiogenesis and genetic alterations. Hypoxia-inducible factor-2α (HIF-2α) plays an essential role in oxygen homeostasis. Expression of HIF-2α-inducible genes is associated with tumor progression. In this study, we investigated this correlation immunohistochemically and using quantitative reverse transcription-polymerase chain reaction to examine various clinical and pathological features in 55 specimens of gastric cancer and 40 specimens of normal gastric tissue. The HIF-2α mRNA expression level and protein expression were significantly higher in gastric cancer tissue samples than in adjacent tissue samples. The positive rates of HIF-2α, matrix metalloprotease-9 (MMP-9), and vascular endothelial growth factor (VEGF) protein were 63.6% (35/55), 80.0% (44/55), and 65.5% (36/55) in gastric cancer tissue specimens, respectively. These values were significantly higher than those in normal gastric tissue samples (P = 0.001, P = 0.000, and P = 0.007, respectively). HIF-2α and MMP-9 were significantly correlated with primary tumor size (P = 0.0065 and P = 0.036, respectively) and invasion depth HIF-2α and gastric adenocarcinoma (P = 0.012 and P = 0.008, respectively). HIF-2α and VEGF were significantly correlated with lymph node involvement (P = 0.030 and P = 0.016, respectively). Expression of HIF-2α was positively correlated with the expression of VEGF and MMP-9 (P = 0.036 and P = 0.000, respectively). These results suggest that HIF-2α is involved in gastric carcinogenesis and disease progression and is a potential therapeutic target for gastric carcinoma.
INTRODUCTION
In gastric cancer, lymph node metastasis and distant metastasis have been established as standard prognostic factors for relapse-free and overall survival. Angiogenesis is a crucial mediator of tumor progression. As tumors expand, diffusion distances from the existing vascular supply increase, resulting in hypoxia (Bohensky et al., 2009 ). Hypoxia-inducible factors (HIFs) drive the survival and development of cancer cells by inducing cellular adaptations as well as angiogenesis and genetic alterations that promote tumor cell survival, proliferation, invasion, and disease progression. As a result, hypoxia and HIFs are associated with poor prognosis in many tumor types (Mole et al., 2009; Mardilovich and Shaw, 2009; Trisciuogglio et al., 2010; Mazumdar et al., 2010; Burrows et al., 2011) . Hypoxia-inducible factor-1α (HIF-1α) has been associated with poor prognosis in a variety of cancers, including uterine, breast, and non-small cell lung cancer, as well as poor response to cancer therapies (Rankin and Giaccia, 2008; Bohensky et al., 2009; Mole et al., 2009; Burrows et al., 2011) . Over 100 HIF target genes have been identified. HIF promotes tumor cell survival and progression by regulating multiple genes, including those involved in angiogenesis [vascular endothelial growth factor (VEGF)], anaerobic metabolism (GLUT1), control of intracellular pH (CA-9), regulation of the cell cycle, DNA damage response, proliferation and apoptosis (p21 and p27), extracellular matrix remodeling and cell migration (lysyl oxidase), and matrix-metalloprotease-1 and -9 (MMP-1 and -9) (Jiang et al., 2003; Meade et al., 2007; Copple et al., 2010; Liu et al., 2011) . The HIF pathway may be a novel therapeutic target for reducing local tumor growth, metastatic burden, and resistance to chemo/radiotherapy. However, little is known regarding the role of HIF-2α in solid tumors. Current data suggest that the response to hypoxia is largely mediated by HIF-1α in endothelial and breast cancer cells but by HIF-2α in renal carcinoma cells. HIF-2α overexpression is important in the development of renal carcinoma in patients with Von Hippel Lindau syndrome. In neuroblastomas, expression of HIF-2α was found to be associated with more aggressive disease. However, other studies in glioblastomas suggested that overexpression of HIF-2α enhances angiogenesis but reduces tumor growth. Although the role of HIF-1α in gastric cancer has been characterized, the relationship between HIF-2α expression, its clinicopathological significance, and prognosis in gastric carcinogenesis is not well understood. In this study, we used immunohistochemistry to examine the expressions of HIF-2α, MMP-9, and VEGF protein in surgical gastric cancer specimens. In addition, we examined the mRNA expression of HIF-2α to evaluate the clinicopathological significance and relationship between each factor. N. Li et al.
MATERIAL AND METHODS

Patients and tumor tissue samples
Fifty-five gastric cancer tissue samples and 40 adjacent tissue samples were obtained from the First Affiliated Hospitals of Xinxiang Medical University between January 2010 and December 2011, snap-frozen, and stored at -70°C. None of the patients had received radiotherapy or chemotherapy prior to surgery. Both tumors were confirmed by pathological examination. All tissue samples were fixed in 10% formalin and embedded in paraffin, and consecutive 4-mm sections were cut. Tissue specimens were examined for the following characteristics: depth of tumor invasion, presence of lymph node involvement, macroscopic and histological type, tumor size, and tumor node metastasis stage. 
Immunohistochemical analysis
The best tissue section for immunohistochemistry was selected. Sections were deparaffinized and rehydrated using graded ethanol, and then endogenous peroxidase was inhibited using 0.3% hydrogen peroxide. For antigen retrieval, slides were boiled in 1 mM ethylenediaminetetraacetic acid, pH 8.0, for 15 min in a microwave oven. Tissue sections were stained with rabbit polyclonal antibody against human HIF-2α (Santa Cruz Biotechnology, Santa Cruz, CA, USA) at 1:100 dilution, rabbit polyclonal antibody against human MMP-9 (Santa Cruz Biotechnology) at 1:100 dilution, and rabbit polyclonal antibody against human VEGF (Jingmei Biotechnology, Beijing, China) at 1:100 dilution. All sections were incubated overnight with primary antibody at 4°C. The sections were then treated with peroxidase using the labeled polymer method with peroxidase for 30 min. Antibody binding was visualized using the Avidin Biotin Complex Elite Kit (Vector Laboratories, Burlingame, CA, USA) and 3,3-diaminobenzine according to manufacturer instructions. Sections were then counterstained with hematoxylin.
Assessment of immunohistochemical staining in tissue sections
Scoring was performed in a double-blinded manner by 2 investigators. Any disagreement was resolved by discussion to obtain final scores. Markers (HIF-2α, MMP-9, and VEGF) in the carcinogenesis study were scored using the same scoring system. The total immunostaining score was calculated as the sum of the percent positivity of stained tumor cells and staining intensity. The percent positivity was scored as "0" (<5%, negative), "1" (5-25%, sporadic), "2" (25-50%, focal), or "3" (>50%, diffuse). Staining intensity was scored as "0" (no staining), "1" (weakly stained), "2" (moderately stained), or "3" (strongly stained). Final expression scores were calculated using the value of percent positivity score x staining intensity score, which ranged from 0-9 as follows: "-" (score 0-3) and "+" (score > 3).
Quantitative reverse transcription-polymerase chain reaction (PCR)
Total RNA was isolated from tissue using Trizol (Gibco, Grand Island, NY, USA). After denaturation of RNA at 94°C for 5 min, 500 ng RNA was reverse-transcribed into cDNA. The cDNA was then amplified using the following primers: HIF-2α sense (5'-tgaaaacgagtccga agcc-3'), antisense (5'-gtggctgacttgaggttga-3'); MMP-9 sense (5'-aggagcggctctccaagaag-3'), antisense (5'-gggcactgcaggatgtcatag-3'); VEGF sense (5'-tacctccaccatgccaagtggt-3'), antisense (5'-aggacgcttgaagatgtac-3'). Duplex amplification was performed using a thermocycler for 30 cycles according to the following program: 1 min at 94°C, 30 s at 50°C (HIF-2α, MMP-9) or 55°C (VEGF), and 1 min at 72°C. PCR products were separated by electrophoresis on a 1.5% agarose gel, with glyceraldehyde 3-phosphate dehydrogenase (580 bp) as an internal standard. PCR products were quantified using the Syngene gel analysis software (Cambridge, UK), and glyceraldehyde 3-phosphate dehydrogenase was used to normalize the data.
Statistical analysis
Data are reported as means ± standard deviation. Correlation between categorical groups was evaluated using the c 2 test or the Fisher exact test. Analysis of variance was conducted and followed by independent-sample Student t-tests. Results were considered to be statistically significant when P < 0.05. Experiments were typically repeated independently 3 times unless indicated otherwise. All data were analyzed using the SPSS 13.0 software (SPSS, Inc., Chicago, IL, USA).
RESULTS
Immunohistochemical differences in HIF-2α, MMP-9, and VEGF between gastric cancer and normal gastric tissue specimens HIF-2α was detected mainly in the epithelium of gastric cancer tissues and less frequently in normal gastric tissues. Strongly positive staining for HIF-2α with a diffuse distribution pattern was identified throughout the mucosa in most adenocarcinomas ( Figure 1A ). In contrast, only weak positive staining for HIF-2α was observed within the cytoplasm of a few normal gastric tissue specimens ( Figure 1B) . Positive HIF-2α expression was detected in 35 of 55 gastric cancer tissue specimens and in 11 of 40 normal gastric tissue specimens. The positive ratio of HIF-2α expression in gastric cancer tissue specimens was significantly higher than that in normal gastric tissue specimens (c 2 = 12.108, P = 0.001) ( MMP-9 was detected mainly in the epithelium of gastric cancer tissues and less frequently in normal gastric tissues. Strongly positive staining for MMP-9 was identified throughout the mucosa in most adenocarcinoma tissues ( Figure 1C ). In contrast, only weak positive staining for MMP-9 was observed within the cytoplasm of a few normal gastric tissue specimens ( Figure 1D ). Positive MMP-9 expression was detected in 44 of 55 gastric cancer tissue specimens and in 13 of 40 normal gastric tissue specimens. The positive ratio of MMP-9 expression in gastric cancer tissue specimens was significantly higher than that in normal gastric tissue specimens (c 2 = 21.771, P = 0.000; Table 2 ). VEGF was detected mainly in the epithelium of gastric cancer tissues and less frequently in normal gastric tissues. Strongly positive staining for VEGF was identified throughout the mucosa in most adenocarcinomas ( Figure 1E ). In contrast, only weak positive staining for VEGF was observed within the cytoplasm of a few normal gastric tissue specimens ( Figure  1F ). Positive VEGF expression was detected in 36 of 55 gastric cancer tissue specimens and in 15 of 40 normal gastric tissue specimens. The positive ratio of VEGF expression in gastric cancer tissue specimens was significantly higher than that in normal gastric tissue specimens (c 2 = 7.278, P = 0.007; Table 2 ).
Expression of HIF-2α mRNA in gastric cancer and adjacent tissue samples
The positive expression rate and relative expression level of HIF-2α mRNA in 55 gastric cancer tissue samples and 40 adjacent normal tissue samples were detected by quantitative reverse transcription-PCR. The positive expression rate and relative expression level of HIF-2α mRNA were significantly higher in gastric cancer tissue samples than in adjacent normal tissue samples (Figure 2 ).
N. Li et al.
Clinicopathological significance of HIF-2α, MMP-9, and VEGF protein expression in gastric cancer
The correlations between HIF-2α, MMP-9, and VEGF protein expression and clinical pathological features of gastric cancer are shown in Table 3 . The positive rates of HIF-2α and MMP-9 were 63.6 and 80.0%, respectively. The VEGF overexpression rate was 65.5%. HIF-2α and MMP-9 were positively correlated with primary tumor size (P = 0.006 and P = 0.036, respectively) and invasion depth (P = 0.012 and P = 0.008, respectively). HIF-2α and VEGF were positively correlated with lymph node involvement (P = 0.030 and P = 0.016, respectively). However, HIF-2α protein expression appeared to be unrelated to age and gender of patients, tumor location, and tumor node metastasis stage, indicating that additional studies are required to resolve these issues. Table 3 . Relationship between protein expression of HIF-2α, MMP-9, VEGF, and clinicopathological parameters.
Correlation between protein HIF-2α and MMP-9/VEGF expression
Spearman's correlation analysis revealed that the expression of HIF-2α was positively associated with that of MMP-9 and VEGF in gastric cancer (r = 0.238, P = 0.036; r = 0.484, P = 0.000; Table 4 ).
DISCUSSION
Recently, molecular markers have been examined for prognostic prediction in gastric cancer patients after curative resection. Although various studies have suggested that several molecular markers should be considered as key prognostic indicators in gastric cancer, no markers are considered to be unified standards in clinical practice (Taylor, 2008; Leonard et al., 2008; Bertout et al., 2009) . Overexpression of HIFs is thought to be correlated with cancer progression. However, the role of HIF-2α in regulating the expression of HIF target genes, such as tumor metastasis-related genes and VEGF, in gastric cancer under hypoxic conditions remains unclear. HIF-2α accumulates in the presence of hypoxia, forms a heterodimer with HIF-1b, and binds to hypoxia-responsive elements. HIF-2α has been shown to regulate a number of the same hypoxia-inducible genes as HIF-1α. However, hypoxia-inducible genes vary in their sensitivity to HIF-1α and HIF-2α and therefore different downstream pathways can be preferentially activated. In the present study, we investigated HIF-2α expression as well as its relationship with MMP-9 and VEGF expression in gastric cancer. The resulting data provide new clues for understanding the molecular mechanisms of the HIF-2α pathway in gastric cancer development.
The HIF-2α expression data showed that HIF-2α mRNA and protein were overexpressed in gastric cancer tissues compared to normal gastric tissues. This result agreed with previous studies showing that HIF-2α was overexpressed in cancers, as assessed by immunochemical histological analysis, including those of the brain, bladder, breast, colon, ovary, pancreas, kidney, and prostate (Rankin et al., 2007 (Rankin et al., , 2009 ). Furthermore, HIF-2α overexpression was significantly correlated with highly aggressive disease and poor prognosis in some cancer types, including breast, ovarian, oligodendroglioma, and oropharyngeal cancers. The HIF-2α pathway is thought to play an important role in gastric carcinogenesis. HIF-2α expression has also been suggested to be critical in the carcinogenesis of renal cortical tumors, ovarian cancer, breast cancer, and lung cancers.
Furthermore, this study showed that increasing HIF-2α and MMP-9 expressions were important in tumor invasiveness and correlated with primary tumor size, in accordance with a previous study (Zhu et al., 2010) . When cultured under hypoxic conditions, breast cancer cells showed increased secretion of another gelatinase, MMP-9 (Copple et al., 2010) . Hypoxia upregulated MMP-2 and MMP-9 activity in a variety of adenocarcinoma cell lines and increased their invasiveness in vitro (Jiang et al., 2003) . To achieve metastasis, a tumor cell must disrupt cell-cell and cell-extracellular matrix contacts, migrate through stromal tissue, invade the basement membrane, and enter/exit the blood stream. These steps are accomplished primarily through the activity of the MMP family of enzymes. Elevated levels of MMPs have been correlated with the invasiveness of several human cancers, as well as with other tumor phenotypes such as angiogenesis, cell proliferation, and resistance to apoptosis. This sug- gests that hypoxia can upregulate MMP-9 and enhance cancer cell invasiveness. HIF-2α may play a role in identifying a patient subgroup that may show a more unfavorable outcome, thus enabling substage-oriented tailored therapy with more intensive treatment and more strict follow-up surveillance.
In this study, our data also indicated that increased HIF-2α and VEGF expression are important in tumor lymph node involvement. Tumor angiogenesis and neovascularization require VEGF expression and the binding of HIF-1α to the VEGF promoter, which is a major pathway resulting in the induction of VEGF expression under hypoxic conditions (Choi et al., 2010) . Interestingly, HIF-2α cannot enhance the expression of VEGF in response to hypoxia in gastric cancer. These results indicate that the role of HIF-2α in the angiogenesis of human gastric cancer may be very complicated. Therefore, we performed an array of in vitro experiments to define the relationship between HIF-2α and VEGF in the angiogenesis of gastric cancer. Based on the major role of HIFs, MMP-9, and VEGF expression levels in gastric cancer progression (Taylor, 2008; Leonard et al., 2008; Bertout et al., 2009) , our study indicates that HIF-2α may be a critical factor promoting tumor aggressiveness in response to hypoxia by mediating the activation of MMP-9 and VEGF in a subset of gastric cancer patients.
Our results strongly indicate that, at least in gastric cancer, HIF-2α plays crucial roles in tumor carcinogenesis and progression. Thus, under hypoxic conditions, HIF-2α in nucleus forms a heterodimer that binds to an enhancer element known as the hypoxia response element in target genes involved in MMP-9 and angiogenesis to regulate the expression of these genes. The results of the present study demonstrate that HIF-2α enhances the expression of MMP-9 and VEGF in response to hypoxia in gastric cancer. These data offer important information that may be used for developing therapies that target angiogenesis and invasion using the HIF pathway in gastric cancer.
The molecular mechanism underlying HIF-2α expression in cancer requires further study (Milovanova et al., 2009 ). The widespread occurrence of up-regulation of HIF-2α in common cancers and the involvement of hypoxia pathways in tumor angiogenesis indicate its importance and wide applicability. Effective chemotherapy and radiation targeting HIF-2α is not well developed Majmundar et al., 2010) . Therefore, further studies are required to evaluate the effects of HIF-2-mediated pathways on human tumor carcinogenesis and progression microenvironments.
